Maxor National Pharmacy Services LLC (Maxor) reported on Thursday that it has signed a specialty pharmacy network distribution agreement with Vertex Pharmaceuticals Inc for the latter's Orkambi and Kalydeco products with immediate effect.
Maxor Specialty, which is comprised of IV Solutions and Pharmaceutical Specialties (PSI), has now been included in Vertex Pharmaceuticals Inc's specialty pharmacy network.
The patients may now get access to Vertex's Orkambi and Kalydeco, two leading medications used in the treatment of certain types of Cystic Fibrosis (CF), through Maxor Specialty.
Established in 1926, Maxor is a leading pharmacy services platform that consists of three primary business segments: MaxorPlus, Maxor Specialty, IV Solutions and Pharmaceutical Specialties as well as Maxor Pharmacy Management and Consulting Services.
Itepekimab meets primary endpoint in one of two Phase 3 COPD trials
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
SalioGen Therapeutics names new chief medical officer
Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis